Allterum Therapeutics
PrivateLast Round
Grant
Sep 9, 2025
Total Funding Raised
$22.42M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Allterum Therapeutics is a clinical-stage biotechnology company developing a monoclonal antibody targeting the interleukin-7 receptor for the treatment of cancers such as Acute Lymphoblastic Leukemia (ALL).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Allterum Therapeutics Comparables
Compare Allterum Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Gyala Therapeutics | 74% | |
| PeproMene Bio | 71% | |
| Xencor, Inc. | 70% |
Allterum Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Sep 9, 2025 | ||||
| Grant | Jun 13, 2025 | ||||
| Grant | Apr 8, 2024 | ||||
| Grant | Jul 19, 2023 | ||||
| Seed | Dec 17, 2020 | ||||
Grant | Apr 21, 2020 |
Allterum Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| Cancer Prevention & Research Institute of Texas | Grant |
| NIH RADx | Grant |
| Fannin Innovation Studio | Seed |
| Cancer Prevention and Research Institute of Texas | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 29, 2026
Monthly visitors grew 270% MoM, from 398 to 1.5K.
- May 18, 2026
Monthly visitors increased 109% MoM.
Allterum Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access